Pemigatinib and futibatinib are approved for advanced cholangiocarcinoma with FGFR2 fusions, while erdafitinib is approved for metastatic urothelial carcinoma with FGFR2 or FGFR3 alterations [235,236]. The gene discussed is FGFR3; the disease is cholangiocarcinoma.